Prevacid Strong Switch Candidate, Experts Say; TAP Works on Follow-on
This article was originally published in The Tan Sheet
Executive Summary
Prevacid's bioavailability combined with the strong safety profile of the PPI class make it a good candidate for an Rx-to-OTC switch, experts say
You may also be interested in...
TAP Licenses Prevacid To Novartis For 2009 Switch
Novartis is developing TAP's Prevacid prescription heartburn and GERD therapy for a 2009 switch to OTC status, the firms announced Dec. 20
Prilosec OTC Making Inroads Into Abbott’s Prevacid
Abbott Labs plans to counter the launch of Prilosec OTC with a broad direct-to-consumer advertising campaign for its Rx proton pump inhibitor Prevacid
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC